Rosenberg Matthew Hamilton trimmed its holdings in Biogen Inc. (NASDAQ:BIIB) by 30.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 182 shares of the biotechnology company’s stock after selling 81 shares during the period. Rosenberg Matthew Hamilton’s holdings in Biogen were worth $52,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. State Street Corp lifted its position in shares of Biogen by 0.4% in the first quarter. State Street Corp now owns 8,262,242 shares of the biotechnology company’s stock worth $2,614,008,000 after buying an additional 30,055 shares in the last quarter. CIBC World Markets Inc. lifted its position in shares of Biogen by 47.8% in the first quarter. CIBC World Markets Inc. now owns 4,762 shares of the biotechnology company’s stock worth $1,507,000 after buying an additional 1,540 shares in the last quarter. FinTrust Capital Advisors LLC lifted its position in shares of Biogen by 41.6% in the first quarter. FinTrust Capital Advisors LLC now owns 620 shares of the biotechnology company’s stock worth $196,000 after buying an additional 182 shares in the last quarter. Tudor Investment Corp Et Al raised its position in Biogen by 15.7% during the first quarter. Tudor Investment Corp Et Al now owns 4,338 shares of the biotechnology company’s stock valued at $1,372,000 after purchasing an additional 590 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in Biogen during the first quarter valued at approximately $443,000. Institutional investors and hedge funds own 83.74% of the company’s stock.

A number of equities research analysts have issued reports on the company. Royal Bank of Canada decreased their price objective on Biogen from $284.00 to $277.00 and set a “sector perform” rating on the stock in a research report on Friday, September 18th. William Blair restated a “hold” rating on shares of Biogen in a research report on Friday, July 10th. Guggenheim restated a “buy” rating and set a $390.00 price objective on shares of Biogen in a research report on Wednesday, July 8th. Barclays downgraded Biogen from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $370.00 to $280.00 in a research report on Monday, June 22nd. Finally, Goldman Sachs Group decreased their price objective on Biogen from $300.00 to $257.00 and set a “neutral” rating on the stock in a research report on Monday, July 13th. Six research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eleven have issued a buy rating to the company. Biogen presently has an average rating of “Hold” and an average price target of $311.96.

BIIB stock traded down $0.62 during midday trading on Friday, reaching $280.01. The stock had a trading volume of 843,290 shares, compared to its average volume of 1,662,454. The stock has a market cap of $44.33 billion, a PE ratio of 8.20, a P/E/G ratio of 1.67 and a beta of 0.54. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.19 and a current ratio of 2.46. The firm has a fifty day simple moving average of $278.53 and a two-hundred day simple moving average of $289.64. Biogen Inc. has a 52-week low of $220.01 and a 52-week high of $374.99.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, July 22nd. The biotechnology company reported $10.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $8.03 by $2.23. The company had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.44 billion. Biogen had a return on equity of 50.10% and a net margin of 40.91%. During the same quarter last year, the business posted $9.15 EPS. On average, sell-side analysts predict that Biogen Inc. will post 34.74 EPS for the current fiscal year.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.

Recommended Story: Moving Average Convergence Divergence (MACD)

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.